In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Denali Therapeutics Inc (NASDAQ: DNLI) closed at $14.92 down -2.86% from its previous closing price of $15.36. In other words, the price has decreased by -$2.86 from its previous closing price. On the day, 1.05 million shares were traded. DNLI stock price reached its highest trading level at $15.29 during the session, while it also had its lowest trading level at $14.83.
Ratios:
For a deeper understanding of Denali Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.27 and its Current Ratio is at 10.27. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $31.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $31 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 12 ’25 when Schuth Alexander O. sold 2,937 shares for $13.58 per share. The transaction valued at 39,884 led to the insider holds 242,346 shares of the business.
Ho Carole sold 2,937 shares of DNLI for $39,884 on Aug 12 ’25. The Chief Medical Officer now owns 217,391 shares after completing the transaction at $13.58 per share. On Aug 13 ’25, another insider, Ho Carole, who serves as the Chief Medical Officer of the company, sold 806 shares for $14.64 each. As a result, the insider received 11,800 and left with 216,585 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNLI now has a Market Capitalization of 2181487104 and an Enterprise Value of 1330508160.
Stock Price History:
The Beta on a monthly basis for DNLI is 1.14, which has changed by -0.48020303 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, DNLI has reached a high of $33.33, while it has fallen to a 52-week low of $10.57. The 50-Day Moving Average of the stock is -1.36%, while the 200-Day Moving Average is calculated to be -4.11%.
Shares Statistics:
For the past three months, DNLI has traded an average of 1.93M shares per day and 1396320 over the past ten days. A total of 145.69M shares are outstanding, with a floating share count of 130.83M. Insiders hold about 10.52% of the company’s shares, while institutions hold 94.22% stake in the company. Shares short for DNLI as of 1760486400 were 14527782 with a Short Ratio of 7.52, compared to 1757894400 on 13079532. Therefore, it implies a Short% of Shares Outstanding of 14527782 and a Short% of Float of 11.12.
Earnings Estimates
. The current rating of Denali Therapeutics Inc (DNLI) is the result of assessments by 15.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.38 and low estimates of -$0.95.
Analysts are recommending an EPS of between -$2.64 and -$3.33 for the fiscal current year, implying an average EPS of -$3.04. EPS for the following year is -$2.83, with 14.0 analysts recommending between -$1.84 and -$3.68.
Revenue Estimates
Based on 18 analysts’ estimates, the company’s revenue will be $85.72M in the next fiscal year. The high estimate is $273.99M and the low estimate is $9.56M.
